Using MRI to guide radiotherapy for cancer treatment
Northern Alberta Linac-MR Image-Guided Human Clinical Trials - 2
This study is testing if using MRI to guide radiotherapy can improve cancer treatment for adults compared to traditional methods.
Quick facts
| Phase | Phase1; Phase2 |
|---|---|
| Study type | Interventional |
| Enrollment | 99 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | AHS Cancer Control Alberta Academic / other |
| Drugs / interventions | radiation |
| Locations | 1 site (Edmonton, Alberta) |
| Trial ID | NCT05413473 on ClinicalTrials.gov |
What this trial studies
This clinical trial evaluates the feasibility of using MR-guided radiotherapy with the Alberta linac-MR P3 system in adult cancer patients. The study progresses through four stages, starting with palliative care and advancing to curative techniques, utilizing MRI instead of traditional CT scans for treatment planning and delivery. Participants will undergo standard radiotherapy procedures while being monitored for adverse events and treatment effectiveness over a follow-up period of up to five years. The goal is to determine the acceptability and potential advantages of this innovative approach in cancer treatment.
Who should consider this trial
Good fit: Ideal candidates are adults aged 18 and older who are fit for external beam radiation therapy.
Not a fit: Patients with contraindications for MRI or those unable to provide informed consent may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could lead to more precise and effective radiotherapy treatments for cancer patients.
How similar studies have performed: While the use of MRI in radiotherapy is being explored, this specific approach with the Alberta linac-MR P3 system is novel and has not been extensively tested in prior studies.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Adults ≥ 18 years of age * Patients deemed fit to undergo external beam radiation therapy by their attending radiation oncologist * Accessible for follow-up Exclusion Criteria: * Patients with contraindications for MRI * Patients who are unable to lie flat and still for the duration of the expected scan acquisition and treatment * Patients who are unable to provide informed consent * Patients with clinically significant inferior treatment plans compared to standard CT based external beam plans. For example, plans that generate hot spots of \> 110% or other unacceptable treatment plans that would not otherwise arise with standard CT based external beam plans. * Pregnancy
Where this trial is running
Edmonton, Alberta
- Cross Cancer Institute — Edmonton, Alberta, Canada (Recruiting)
Study contacts
- Principal investigator: Nawaid Usmani, MD — Cross Cancer Institute, Alberta Health Services
- Study coordinator: Nawaid Usmani, MD
- Email: Nawaid.Usmani@ahs.ca
- Phone: 780-432-8518
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.